trial
as of 2026-07-01NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
NCTId NCT01393600
at a glance
Phase 2 · Completed
Enrollment 37 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2012-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2011-08
Primary completion
2012-02
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Christopher O'Brien, MDStudy Director
Sites
11 total
Little Rock, United StatesNational City, United StatesSan Diego, United StatesSan Diego, United StatesMiami, United StatesMiami, United StatesNorth Miami, United StatesAtlanta, United StatesSt Louis, United StatesSan Antonio, United StatesCharleston, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
37
Phase
PHASE2
Primary Completion Date
2012-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator
person